Elegant Solutions for Complex Issues

Needle-free Intranasal Drug Delivery with
MAD ®  Nasal
Mucosal Atomization Device


Shouldn't you add this drug delivery option to your therapeutic armamentarium?

Fast, effective and painless treatment for:
         Acute pain                     Sickle Cell Crisis
                Burns                             Sedation and Anxiolysis
  Fractures                       Seizures         
      Trauma                          Opiate overdose

Reduce pain and bleeding associated with:
      Nasal and oral instrumentation
  Nasogastric tube placement


                    Key Features Nasal Oral I.M. I.V.  
  High Serum Drug Levels YES NO + / - YES                                
  Rapid Onset YES NO + / - YES  
  Titratable YES NO NO YES  
  Painless YES YES NO NO  
  Easy to Use YES YES + / - NO  
  Low Resource Utilization YES YES + / - NO  
  Eliminates needle stick risk YES YES NO NO  


Specifications
Typical particle size 30 - 100 microns
System dead space 0.09 mL
Tip diameter 0.17 inches (4.3 mm)
Applicator length
 		 1.75 inches (4.5 cm)

Ordering Information
100 units per case or 25 units per box.
 MAD100: Mucosal Atomization Device with luer lock connector and 3 mL syringe preattached.
 MAD140: Mucosal Atomization Device with luer lock connector, vial adapter and 3 mL syringe preattached.
 MAD300: Mucosal Atomization Device with luer lock connector. Syringe not included.
  Reliable atomization of topical solutions across the nasal and oropharyngeal mucous membranes.

Safe and Painless
  • No needle - No shot - No pain
  • No risk of needlestick
  • Less frightening for children
  • Disposable

    Rapidly Effective
  • Atomized nasal medications absorb directly into the blood stream, avoiding first pass metabolism
  • Atomized medications absorb directly into the brains and CSF via the olfactory mucosa (nose-brain pathway)
  • Achieves serum medication levels comparable to injections

    Controlled administration
  • Exact dosing, exact volume
  • Titratable to effect (repeat if needed)
  • Atomizes in any position
  • Atomized particles are optimal size for deposition across broad area of mucosa

    Minimal Resource Utilization
  • Nasal drug administration is quick and easy
  • No sterile technique is required
  • Eliminates IV set-up time

    Evidence Based
  • Extensive literature supports the clinical effectiveness of medications delivered via the MAD nasal

    All MAD® products are:
  • With luer lock connection
  • Individually packaged clean
  • Available with or without 3 mL syringe
  • Latex-free




    • More Products

    To Place an Order, Or For Additional Information

    MAD Nasal Devices:

    Photo of MAD nasal 100, 140 and 300

    Billing CPT codes for clinicians

    There is at least one billing CPT code for intranasal drug delivery: CPT 99142. You will need to review this with your professional billing agent to be sure this is up to date. It is related to sedation:

    99141: Sedation with or without analgesia; intravenous, intramuscular, or inhalation

    99142: Sedation with oral, rectal and/or intranasal

     Education Center

    MAD nasal mod-high resolution photo (1.2 MB JPG)

    MAD Nasal - How to use it (download a Power Point presentation - 12.7 MB)

    MAD Nasal - How to use it - Video Slides presentation (16 minutes)

    Nasal Drug Delivery - Overview of the concept - slides

    Nasal Drug Delivery - Overview of the concept - Video slides 22.5 minutes

    Abstract Booklets:

    1. Topical Anesthetic prior to nasopharyngeal procedures
    2. Benzocaine induced Methemoglobinemia

    Newsletters:

    1. Risks of topical phenylephrine in pediatric patients
    References (selected) - for complete list visit www.pubmed.gov or an internet search engine and conduct a literature search for "intranasal medications" or other more specific key words of interest.

    Ahmad, S., J. C. Ellis, et al. (2006). "Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomised trial." Lancet 367(9522): 1591-7.

    Barton, E. D., C. B. Colwell, et al. (2005). "Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting." J Emerg Med 29(3): 265-71.

    Bates, B. A., S. A. Schutzman, et al. (1994). "A comparison of intranasal sufentanil and midazolam to intramuscular meperidine, promethazine, and chlorpromazine for conscious sedation in children." Ann Emerg Med 24(4): 646-51.

    Bhattacharyya, Kalra, et al. (2006). "Intranasal midazolam vs rectal diazepam in acute childhood seizures." Pediatr Neurol 34(5): 355-9.

    Borland, M. L., L. J. Clark, et al. (2008). "Comparative review of the clinical use of intranasal fentanyl versus morphine in a paediatric emergency department." Emerg Med Australas 20(6): 515-20.

    Borland, M., I. Jacobs, et al. (2007). "A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department." Ann Emerg Med 49(3): 335-40.

    Carr, D. B., L. C. Goudas, et al. (2004). "Safety and efficacy of intranasal ketamine in a mixed population with chronic pain." Pain 110(3): 762-4.

    Gharde, P., S. Chauhan, et al. (2006). "Evaluation of efficacy of intranasal midazolam, ketamine and their mixture as premedication and its relation with bispectral index in children with tetralogy of fallot undergoing intracardiac repair." Ann Card Anaesth 9(1): 25-30.

    Gilchrist, F., A. M. Cairns, et al. (2007). "The use of intranasal midazolam in the treatment of paediatric dental patients." Anaesthesia 62(12): 1262-5.

    Good, P., K. Jackson, et al. (2009). "Intranasal sufentanil for cancer-associated breakthrough pain." Palliat Med 23(1): 54-8.

    Harbord, M. G., N. E. Kyrkou, et al. (2004). "Use of intranasal midazolam to treat acute seizures in paediatric community settings." J Paediatr Child Health 40(9-10): 556-8.

    Heard, C., P. Creighton, et al. (2009). "Intranasal flumazenil and naloxone to reverse over-sedation in a child undergoing dental restorations." Paediatr Anaesth 19(8): 795-7; discussion 798-9.

    Hollenhorst, J., S. Munte, et al. (2001). "Using intranasal midazolam spray to prevent claustrophobia induced by MR imaging." AJR Am J Roentgenol 176(4): 865-8.

    Holsti, M., B. L. Sill, et al. (2007). "Prehospital intranasal midazolam for the treatment of pediatric seizures." Pediatr Emerg Care 23(3): 148-53.

    Kelly, A. M., D. Kerr, et al. (2005). "Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose." Med J Aust 182(1): 24-7.

    Krempl, G. A. and A. D. Noorily (1995). "Use of oxymetazoline in the management of epistaxis." Ann Otol Rhinol Laryngol 104(9 Pt 1): 704-6.

    Lahat, E., M. Goldman, et al. (2000). "Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study." Bmj 321(7253): 83-6.

    Lane, R. D. and J. E. Schunk (2008). "Atomized intranasal midazolam use for minor procedures in the pediatric emergency department." Pediatr Emerg Care 24(5): 300-3.

    Rickard, C., P. O'Meara, et al. (2007). "A randomized controlled trial of intranasal fentanyl vs intravenous morphine for analgesia in the prehospital setting." Am J Emerg Med 25(8): 911-7.

    Talon, M. D., L. C. Woodson, et al. (2009). "Intranasal dexmedetomidine premedication is comparable with midazolam in burn children undergoing reconstructive surgery." J Burn Care Res 30(4): 599-605.

    Telfer, P. T., C. Lahoz, et al. (2009). "Intranasal diamorphine for acute sickle cell pain." Arch Dis Child.

    Wermeling, D. P. (2009). "Intranasal delivery of antiepileptic medications for treatment of seizures." Neurotherapeutics 6(2): 352-8.

    Wolfe, T. (2007). "Intranasal fentanyl for acute pain: techniques to enhance efficacy." Ann Emerg Med 49(5): 721-2.

    Wolfe, T. R., D. E. Fosnocht, et al. (2000). "Atomized lidocaine as topical anesthesia for nasogastric tube placement: A randomized, double-blind, placebo-controlled trial." Ann Emerg Med 35(5): 421-5.

    Wolfe, T. R. and T. C. Macfarlane (2006). "Intranasal midazolam therapy for pediatric status epilepticus." Am J Emerg Med 24(3): 343-6.


    Resources
    1. Download MAD Nasal Sales Sheet

     
    Email Us